All section Close
Credits: TheIndianExpress
Serum Institute Of India Gets DCGI Nod For Phase 2, 3 Trials Of Oxford Vaccine
Writer: Devyani Madaik
A media enthusiast, Devyani believes in learning on the job and there is nothing off limits when it comes to work. Writing is her passion and she is always ready for a debate as well.
India, 3 Aug 2020 11:29 AM GMT | Updated 4 Aug 2020 3:43 AM GMT
Editor : Shubhendu Deshmukh |
Shubhendu, the quint essential news junky, the man who loves science and politics in equal measure and offers the complete contrast to it by being a fan of urdu poetry as well.
Creatives : Abhishek M
" An engineer by profession, Abhishek is the creative producer of the team, graphic designing is his passion and travelling his get away. In more ways than one, he makes the content visually appealing."
The DCGI approval comes after thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
The Drug Controller General Of India (DCGI) V.G. Somani on Tuesday gave approval to the Serum Institute of India (SII) for conducting Phase II and Phase III clinical trials of Oxford University-AstraZeneca COVID-19 vaccine COVISHIELD.
The SII is manufacturing the vaccine developed by the Jenner Institute (Oxford University) in association with AstraZeneca.
The DCGI approval comes after thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19, reported India Today.
Earlier in July, the SII had submitted an application seeking permission for conducting the trials. Following, the institute submitted a revised proposal according to which 1,600 people aged above 18 years will participate in the trials across 17 selected sites in India.
This includes AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.
However, the firm has to submit safety data, assessed by the Data Safety Monitoring Board (DSMB), to the Central Drugs Standard Control Organisation (CDSCO) before moving forward to Phase III trials, a senior official told the media.
"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official as quoted.
The United Kingdom and South Africa have started with Phase II and III trials of the vaccine, while Brazil has initiated the third phase and has shown an acceptable profile.
Also Read: Delhi Records Lowest COVID Death Since June, Less Than 1,000 Fresh Cases
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
